Cardiogen Research: Cardiac Bioregulator Peptide Studies

Last updated: June 2026

Cardiogen is a synthetic four-amino acid peptide derived from cardiac tissue fractions. The sequence is Ala-Glu-Asp-Arg. Khavinson lab research first described this compound as a cardiac-tissue bioregulator. Lab studies measured changes in mRNA levels in treated cardiac cell lines. Findings come from cell and animal models only. No human clinical trial data are published for Cardiogen. Research-grade Cardiogen is available at ≥99% purity, COA-verified for lab use only.

A Cardiogen research compound is a synthetic short peptide derived from cardiac tissue fractions. Khavinson lab research first described it as a cardiac-tissue bioregulator. Lab studies have checked its effects on gene output in cardiac cell models. Researchers measured changes in mRNA levels in treated cell lines vs controls. Research-grade Cardiogen requires ≥99% purity by HPLC and mass spec before lab use.

Next Level Pharm is a US supplier of research-grade peptides, including Cardiogen. Each vial is verified to ≥99% purity by HPLC and mass spec. The COA ships with every order and includes a lot of numbers. The average purity across the last 100 batches is 99.4%. This compound is for lab research use only.

Knowing the tissue of origin of Cardiogen helps researchers plan lab protocols. It belongs to a class of short tissue-derived peptides known as bioregulator peptides. Khavinson lab research described this class over several decades.

Key Takeaways

1. Cardiogen Is a Short Four-Amino Acid Peptide: It was derived from cardiac muscle tissue in Khavinson lab research. This tissue origin shapes the focus of lab studies.
2. Cardiac Tissue Is the Source of Origin: Lab studies used cardiac cell lines. Cell culture work checked gene output changes vs controls.
3. Cell Culture Studies Examined Gene Output: Treated cell lines showed changes in mRNA levels in vitro. These findings do not apply to human biology.
4. Mass Spec Confirms the Low Molecular Weight: Cardiogen is a short peptide with a low mass. Mass spec identifies its exact weight with high detail.
5. Research-Grade Cardiogen Is for Lab Use Only: It is not FDA-approved. Each batch ships with a COA showing HPLC and mass spec data.

Researchers sourcing Cardiogen for lab use should verify the COA before any study. HPLC must confirm ≥99% purity. Mass spec must confirm the correct molecular weight for each batch.

What Is Cardiogen and Where Does It Come From?

Cardiogen is a synthetic short peptide bioregulator first described in Khavinson lab research. The compound was derived from cardiac muscle tissue fractions by acid extraction and column sorting. The peptide chain was later reproduced by lab synthesis for research use.

Synthetic Cardiogen is now made by solid-phase peptide synthesis (SPPS). This method builds the chain step by step on a solid resin. The chain is then released and purified. SPPS allows exact replication of the sequence with controlled purity.

According to a study in PubMed (2016), Khavinson and colleagues described short cardiac-derived peptides and their effects on gene output in cell models. The research used in vitro methods with cardiac-type cell lines. These findings do not apply to human clinical use.

What Is the Structure of Cardiogen?

Cardiogen is a short peptide chain of four amino acids. As a four-amino acid compound, it has a low molecular weight. Short peptides of this length can enter cell nuclei and interact with chromatin in lab studies.

The low molecular weight is a research advantage for mass spec testing. Mass spec can identify short peptide masses with high detail and precision. A correct result confirms the compound is not truncated or changed in any way.

According to a review in Molecules (2021), short four-amino acid peptides from organ tissue fractions were shown to interact with chromatin near gene promoters. Cell culture studies confirmed these findings in vitro. Changes in mRNA output were measured in treated cells vs controls.

What Did Cell Culture Studies Show About Cardiogen?

Cell culture studies used cardiac-type cell lines to examine Cardiogen effects. Researchers measured gene output changes after treatment in vitro. Changes in mRNA levels for cardiac-linked genes were reported in treated cells vs controls.

The proposed mechanism involves the short peptide entering the cell nucleus and binding chromatin regions. This binding may alter gene switch access at promoter sites. These changes have been observed in cell culture assays only.

What Did Animal Model Studies Find for Cardiogen?

Animal model research has extended the cell culture findings for Cardiogen. Rodent studies checked tissue-linked markers after treatment with the compound. Researchers observed changes in cardiac tissue parameters in treated animals vs controls.

All animal findings come from non-human studies. They do not provide evidence for Cardiogen effects in humans. This compound is not approved for any human clinical use. The findings are part of preclinical lab research only.

According to a review in Biogerontology (2010), Khavinson lab rodent studies showed changes in tissue-linked gene output after short bioregulator peptide treatment. Research focused on organ-specific cell biology in aging animal models. All work was in non-human subjects.

Bioregulator	Tissue Source	Amino Acids	Research Focus
Cardiogen	Cardiac	4	Cardiac cell gene output
Cartalax	Cartilage	4	Cartilage cell gene output
Cortagen	Nerve	4	Cortical tissue gene models
Crystagen	Eye	3	Retinal cell culture studies
Epithalon	Pineal	4	Pineal gland aging models

How Does Cardiogen Fit into Bioregulator Research?

Cardiogen belongs to the bioregulator peptide class first described by Dr. Vladimir Khavinson. These are short tissue-derived peptides studied for effects on gene output in cell models. Each compound is linked to one specific tissue of origin

Cardiogen is the cardiac-origin compound in this class. Cartalax is from cartilage. Cortagen is from nerve tissue. All are sold as separate lyophilized vials at Next Level Pharm. Each vial has its own COA with HPLC and mass spec data.

How Is Research-Grade Cardiogen Purity Confirmed?

Research-grade Cardiogen is tested by HPLC and mass spec before shipping. HPLC confirms the compound is ≥99% pure in the batch. Mass spec confirms the molecular weight matches the expected mass for the four-amino acid sequence.

Short peptides like Cardiogen have low masses that mass spec identifies with high detail. A mismatch would signal a truncated or wrong peptide. Shop research peptides at Next Level Pharm to view COA data. Each batch is rejected if purity falls below ≥99%.

Frequently Asked Questions

What Is Cardiogen?

Cardiogen is a synthetic short peptide bioregulator derived from cardiac tissue in Khavinson lab research. It is a chain of four amino acids with a low molecular weight. Lab studies have checked its effects on gene output in cardiac cell models. It is not FDA-approved and is for lab research only, with a COA showing HPLC and mass spec data on every batch.

What Is the Tissue Origin of Cardiogen?

Cardiogen was derived from cardiac muscle tissue fractions by acid extraction and column sorting in Khavinson lab work. This cardiac origin shapes the focus of lab studies. Studies use cardiac cell lines and gene output markers linked to cardiac cell biology. Tissue origin is a key design feature of this research. It does not confirm selective activity in human cardiac tissue.

What Happened in Cardiogen Cell Culture Studies?

Cell culture studies used cardiac-type cell lines treated with Cardiogen. Researchers measured gene output changes in treated cells vs controls. These included mRNA levels for cardiac-linked genes. The proposed mechanism involves the short peptide entering the cell nucleus and binding chromatin near promoter regions. All findings come from in vitro models only.

What Happened in Cardiogen Animal Model Studies?

Rodent studies examined tissue-linked markers after Cardiogen treatment. Changes in cardiac-related parameters were observed in treated animals vs controls. All findings come from non-human animal models. They do not provide human clinical evidence. Research-grade Cardiogen is not approved for any human clinical application.

What Is a Bioregulator Peptide?

A bioregulator peptide is a short amino acid chain, typically 2-4 amino acids, derived from a specific tissue. Khavinson lab research described this class in the 1980s onward. Each compound is linked to one tissue of origin. Lab studies use cell lines from that same tissue. Synthetic bioregulators are made by SPPS and verified to ≥99% purity by HPLC and mass spec.

What Is the Molecular Weight of Cardiogen?

Cardiogen is a short four-amino acid peptide with a low molecular weight. Short peptides in the 2-4 amino acid range have masses below 500 Da. Mass spec identifies these low masses with high detail. A correct result confirms the full four-amino acid sequence is present. Any mismatch signals a truncated or changed form.

How Does Cardiogen Compare to Other Bioregulators?

Cardiogen is the cardiac-origin compound in the Khavinson class. Cartalax is from cartilage, and Cortagen is from nerve tissue. All are short four-amino acid peptides. Each is verified to ≥99% purity by HPLC and mass spec before shipping. Researchers should source each compound separately and verify its COA before any lab study.

How Is Research-Grade Cardiogen Purity Confirmed?

HPLC confirms ≥99% purity for Cardiogen in each production batch. Mass spec confirms the molecular weight matches the expected mass for the four-amino acid sequence. A COA with both results is required for every batch. Batches that fail either test are rejected before shipping to researchers.

Is Cardiogen Available for Lab Research?

Yes, research-grade Cardiogen is available as a lyophilized vial for lab use. Each vial is verified to ≥99% purity by HPLC and mass spec. It ships with a COA showing both results for that batch. Cardiogen is not FDA-approved and is not for human use. Researchers should verify the COA before any lab study begins.

Summary

Cardiogen is a synthetic short peptide bioregulator derived from cardiac tissue fractions. Khavinson lab research described this four-amino acid compound and its tissue-linked effects on gene output in cell and animal models.

Cell culture studies showed changes in mRNA levels for cardiac-linked genes in treated cell lines. Animal studies showed changes in tissue markers in rodent models. None of these findings apply to human clinical use.

Research-grade Cardiogen requires ≥99% purity by HPLC and mass spec on every batch.

What Should You Do Next?

Researchers sourcing Cardiogen should verify three items on every COA. First, confirm HPLC purity is ≥99%. Second, confirm mass spec shows the correct molecular weight for the four-amino acid chain. Third, record the lot number for batch records.

Shop research peptides. Every Cardiogen batch ships with HPLC and mass spec data and a traceable lot number.

People Also Read

• Epithalon Research Explained: What Current Studies Show
• What Are Longevity Peptides? A Complete Research Review

About the Author

Next Level Pharm Research Team

Alex M covers peer-reviewed findings in peptide science for Next Level Pharm, a US-based supplier of research-grade peptides verified to ≥99% purity via HPLC and mass spectrometry on every batch.

Disclaimer: The information provided on this page is for educational and research purposes only. Next Level Pharm products are intended for laboratory research use only. They are not intended for human consumption, diagnostic, therapeutic, or medicinal purposes. This content does not constitute medical advice. Always consult a licensed healthcare professional before making any health-related decisions.